IL156828A0 - Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes - Google Patents
Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetesInfo
- Publication number
- IL156828A0 IL156828A0 IL15682802A IL15682802A IL156828A0 IL 156828 A0 IL156828 A0 IL 156828A0 IL 15682802 A IL15682802 A IL 15682802A IL 15682802 A IL15682802 A IL 15682802A IL 156828 A0 IL156828 A0 IL 156828A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor ligand
- gastrin
- subjects
- composition
- therapy methods
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000002035 prolonged effect Effects 0.000 title abstract 3
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 title abstract 2
- 102000004859 Cholecystokinin Receptors Human genes 0.000 title abstract 2
- 108090001085 Cholecystokinin Receptors Proteins 0.000 title abstract 2
- 102000001301 EGF receptor Human genes 0.000 title abstract 2
- 108060006698 EGF receptor Proteins 0.000 title abstract 2
- 102000052874 Gastrin receptors Human genes 0.000 title abstract 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 230000009707 neogenesis Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26163801P | 2001-01-12 | 2001-01-12 | |
| PCT/US2002/000685 WO2002055152A2 (fr) | 2001-01-12 | 2002-01-11 | Efficacite prolongee de methodes de soins de neogenese d'ilot avec une composition de ligand de recepteur de gastrine/cck et de ligand de recepteur d'egf chez des sujets a diabetes preexistants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL156828A0 true IL156828A0 (en) | 2004-02-08 |
Family
ID=22994183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15682802A IL156828A0 (en) | 2001-01-12 | 2002-01-11 | Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6992060B2 (fr) |
| EP (1) | EP1351742B1 (fr) |
| JP (1) | JP2004520345A (fr) |
| KR (1) | KR20040064605A (fr) |
| CN (1) | CN1486204A (fr) |
| AT (1) | ATE411077T1 (fr) |
| AU (1) | AU2002243501B2 (fr) |
| CA (1) | CA2434330A1 (fr) |
| DE (1) | DE60229352D1 (fr) |
| ES (1) | ES2315350T3 (fr) |
| IL (1) | IL156828A0 (fr) |
| WO (1) | WO2002055152A2 (fr) |
| ZA (1) | ZA200305347B (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US20040037818A1 (en) * | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
| US20060014684A1 (en) * | 2000-03-03 | 2006-01-19 | University Technologies International Inc. | Novel uses of EGF |
| JP2004520345A (ja) | 2001-01-12 | 2004-07-08 | ワラター・ファーマシューティカルズ・インク | 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続 |
| JP3993560B2 (ja) * | 2001-08-30 | 2007-10-17 | ステム セル セラピューティクス インコーポレイテッド | 神経幹細胞の分化およびその治療用途 |
| CA2460184A1 (fr) | 2001-09-14 | 2003-03-27 | Stem Cell Therapeutics Inc. | Augmentation du nombre de cellules souche neuronales induites par la prolactine |
| US20030054551A1 (en) * | 2001-09-18 | 2003-03-20 | Stem Cell Therapeutics Inc. | Effect of growth hormone and IGF-1 on neural stem cells |
| US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| WO2003035102A1 (fr) * | 2001-10-26 | 2003-05-01 | University Technologies International, Inc. | Utilisation de l'egf pour inhiber les infections pathogenes du tractus urogenital |
| US20060234373A1 (en) * | 2002-05-24 | 2006-10-19 | Alex Rabinovitch | Treatment for diabetes |
| CN100448483C (zh) * | 2002-05-24 | 2009-01-07 | 瓦拉塔药品公司 | 糖尿病的治疗 |
| DE60329724D1 (de) * | 2002-06-07 | 2009-11-26 | Waratah Pharmaceuticals Inc | Methoden und Kompositionen um Diabetes zu behandeln |
| EP1837031B1 (fr) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Methodes et compositions pour le traitement du diabete |
| CA2492442A1 (fr) * | 2002-07-31 | 2004-02-05 | Stem Cell Therapeutics Inc. | Procede d'amelioration de la proliferation, de la differentiation et de la survie de cellules souches neurales au moyen du polypeptide d'activation d'adenylate cyclase hypophysaire (pacap) |
| US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
| US20040209801A1 (en) | 2002-10-22 | 2004-10-21 | Brand Stephen J. | Treatment of diabetes |
| WO2004037277A2 (fr) * | 2002-10-24 | 2004-05-06 | Mcgill University | Procede et composition pour la regression du diabete et utilisations correspondantes |
| CN1829528A (zh) * | 2003-05-27 | 2006-09-06 | 瓦拉塔药品公司 | 包含胃泌素化合物的组合物及其在糖尿病中的应用 |
| US20080039379A1 (en) * | 2003-05-27 | 2008-02-14 | Waratah Pharmaceuticals, Inc. | Compositions Comprising Gastrin Compounds and Their Use in Diabetes |
| US20070111932A1 (en) * | 2003-07-31 | 2007-05-17 | Stem Cell Therapeutics Inc. | Method of enhancing and/or inducing neuronal migration using erythropoietin |
| RU2006131046A (ru) * | 2004-01-30 | 2008-03-10 | Уэрейта Фармасьютикалз, Инк. (Ca) | Совместное применение агониста glp-1 и соединений гастрина |
| US7846898B2 (en) * | 2004-02-13 | 2010-12-07 | Stem Cell Therapeutics Corp. | Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis |
| EP1765873A4 (fr) * | 2004-07-01 | 2009-07-01 | Waratah Pharmaceuticals Inc | Utilisation combinee d'agoniste cd3 et de gastrine pour le traitement du diabete |
| AU2005291810B2 (en) | 2004-10-07 | 2011-12-08 | Stem Cell Therapeutics Corp. | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
| WO2007036033A1 (fr) | 2005-09-27 | 2007-04-05 | Stem Cell Therapeutics Corp. | Regulation par la prolactine de la proliferation des cellules precurseurs d'oligodendrocytes |
| EP1951286A4 (fr) * | 2005-10-07 | 2009-11-04 | Waratah Pharmaceuticals Inc | Utilisation combinee d'inhibiteurs de la dpp-iv et de composes gastrine |
| HUE037129T2 (hu) * | 2005-12-15 | 2018-08-28 | Nestec Sa | Kompozíciók és eljárások agyi funkció megõrzésére |
| KR101872061B1 (ko) | 2005-12-19 | 2018-06-27 | 파마인 코포레이션 | 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이 조성물의 제조 방법 및 그 조성물의 이용 방법 |
| JP2009530234A (ja) * | 2006-03-17 | 2009-08-27 | ステム セル セラピューティクス コーポレイション | 神経変性疾患の治療のためのｌｈまたはｈｃｇ、およびｅｐｏについての投与レジメン |
| KR101080955B1 (ko) * | 2006-07-14 | 2011-11-08 | 포항공과대학교 산학협력단 | 인슐린 분비를 증가시키고 혈당을 감소시키는 표피성장인자 |
| WO2008106775A1 (fr) * | 2007-03-02 | 2008-09-12 | Waratah Pharmaceuticals Inc. | Traitement d'association du diabète à l'aide d'un ligand du récepteur de l'egf et d'un composé de gastrine |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
| US20090176892A1 (en) * | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
| US10240138B2 (en) | 2008-06-12 | 2019-03-26 | Ipsen Bioinnovation Limited | Polypeptides that bind to and inhibit secretion from growth hormone secreting cells |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| WO2011131646A1 (fr) * | 2010-04-20 | 2011-10-27 | Novo Nordisk A/S | Dérivés de gastrine à action prolongée |
| KR102027750B1 (ko) * | 2018-05-03 | 2019-10-02 | 연세대학교 산학협력단 | 당 배출용 조성물 |
| KR102508141B1 (ko) * | 2019-07-01 | 2023-03-10 | 주식회사 연세대학교 바이오헬스기술지주회사 | 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물 |
| KR102109385B1 (ko) * | 2019-08-21 | 2020-05-12 | 연세대학교 산학협력단 | 당 배출용 조성물 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE38892B1 (en) | 1973-03-28 | 1978-06-21 | Ici Ltd | Pharmaceutical compositions |
| JPS6028994A (ja) * | 1983-07-08 | 1985-02-14 | Wakunaga Seiyaku Kk | 〔２１―ロイシン〕ヒトウロガストロン |
| GB8409961D0 (en) | 1984-04-17 | 1984-05-31 | Searle & Co | Pharmaceutical compositions |
| US4686283A (en) | 1985-04-16 | 1987-08-11 | Syntex (U.S.A.) Inc. | Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis |
| US5102789A (en) | 1989-03-15 | 1992-04-07 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Production of epideramal growth factor in pichia pastoris yeast cells |
| US5158935A (en) | 1989-05-12 | 1992-10-27 | Chiron Corporation | Human epidermal growth factor having substitution at position 11 |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| US5434135A (en) | 1990-08-02 | 1995-07-18 | Indu Parikh | Growth factor compositions, preparation and use |
| AU2489992A (en) | 1991-08-16 | 1993-03-16 | Chiron Corporation | Muteins of epidermal growth factor exhibiting enhanced binding at low ph |
| US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| US5885956A (en) * | 1992-12-14 | 1999-03-23 | Research Triangle Pharmaceuticals | Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand |
| JPH09511384A (ja) | 1994-01-24 | 1997-11-18 | リサーチ トライアングル ファーマシューティカルズ リミテッド | 若年型糖尿病の治療 |
| GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US20040037818A1 (en) | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
| AU2153500A (en) | 1998-11-19 | 2000-06-05 | Millennium Pharmaceuticals, Inc. | Egf-like nucleic acids and polypeptides and uses thereof |
| CA2362593A1 (fr) | 1999-02-10 | 2000-08-17 | Curis, Inc. | Cellules progenitrices de pancreas et procedes et utilisations associees |
| US6610535B1 (en) | 2000-02-10 | 2003-08-26 | Es Cell International Pte Ltd. | Progenitor cells and methods and uses related thereto |
| JP2004520345A (ja) | 2001-01-12 | 2004-07-08 | ワラター・ファーマシューティカルズ・インク | 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続 |
| CA2442177A1 (fr) | 2001-03-29 | 2002-10-10 | Ixion Biotechnology, Inc. | Procede de transdifferentiation de cellules souches non pancreatiques dans la voie de differentiation du pancreas |
| US7037504B2 (en) | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| US20060234373A1 (en) | 2002-05-24 | 2006-10-19 | Alex Rabinovitch | Treatment for diabetes |
| EP1837031B1 (fr) | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Methodes et compositions pour le traitement du diabete |
| DE60329724D1 (de) | 2002-06-07 | 2009-11-26 | Waratah Pharmaceuticals Inc | Methoden und Kompositionen um Diabetes zu behandeln |
| US20040209801A1 (en) | 2002-10-22 | 2004-10-21 | Brand Stephen J. | Treatment of diabetes |
| US20040229810A1 (en) | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
| AU2003228097A1 (en) | 2003-04-28 | 2004-11-23 | Pirelli Pneumatici S.P.A. | Pneumatic tire provided with a multi-layered tread and process for its manufacture |
| CN1829528A (zh) | 2003-05-27 | 2006-09-06 | 瓦拉塔药品公司 | 包含胃泌素化合物的组合物及其在糖尿病中的应用 |
| RU2006131046A (ru) | 2004-01-30 | 2008-03-10 | Уэрейта Фармасьютикалз, Инк. (Ca) | Совместное применение агониста glp-1 и соединений гастрина |
| EP1765873A4 (fr) | 2004-07-01 | 2009-07-01 | Waratah Pharmaceuticals Inc | Utilisation combinee d'agoniste cd3 et de gastrine pour le traitement du diabete |
| EP1951286A4 (fr) | 2005-10-07 | 2009-11-04 | Waratah Pharmaceuticals Inc | Utilisation combinee d'inhibiteurs de la dpp-iv et de composes gastrine |
| EP1971363A1 (fr) | 2005-12-02 | 2008-09-24 | Waratah Pharmaceuticals, Inc. | Polythérapies avec des agonistes de la gastrine pour le diabète et des maladies apparentées |
| WO2007095737A1 (fr) | 2006-02-21 | 2007-08-30 | Waratah Pharmaceuticals Inc. | Polythérapie pour le traitement du diabète, comprenant un agoniste d'exendine et un composé de gastrine |
-
2002
- 2002-01-11 JP JP2002555881A patent/JP2004520345A/ja active Pending
- 2002-01-11 ES ES02708990T patent/ES2315350T3/es not_active Expired - Lifetime
- 2002-01-11 EP EP02708990A patent/EP1351742B1/fr not_active Expired - Lifetime
- 2002-01-11 DE DE60229352T patent/DE60229352D1/de not_active Expired - Fee Related
- 2002-01-11 AU AU2002243501A patent/AU2002243501B2/en not_active Ceased
- 2002-01-11 CA CA002434330A patent/CA2434330A1/fr not_active Abandoned
- 2002-01-11 IL IL15682802A patent/IL156828A0/xx unknown
- 2002-01-11 CN CNA028036824A patent/CN1486204A/zh active Pending
- 2002-01-11 US US10/044,048 patent/US6992060B2/en not_active Expired - Fee Related
- 2002-01-11 AT AT02708990T patent/ATE411077T1/de not_active IP Right Cessation
- 2002-01-11 WO PCT/US2002/000685 patent/WO2002055152A2/fr active Application Filing
- 2002-01-11 KR KR10-2003-7009347A patent/KR20040064605A/ko not_active Application Discontinuation
-
2003
- 2003-07-10 ZA ZA200305347A patent/ZA200305347B/en unknown
-
2005
- 2005-11-14 US US11/273,615 patent/US7476388B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1486204A (zh) | 2004-03-31 |
| EP1351742A2 (fr) | 2003-10-15 |
| WO2002055152A3 (fr) | 2003-04-10 |
| US20020098178A1 (en) | 2002-07-25 |
| AU2002243501B2 (en) | 2007-11-22 |
| WO2002055152A8 (fr) | 2002-11-14 |
| US6992060B2 (en) | 2006-01-31 |
| CA2434330A1 (fr) | 2002-07-18 |
| WO2002055152A2 (fr) | 2002-07-18 |
| ATE411077T1 (de) | 2008-10-15 |
| US7476388B2 (en) | 2009-01-13 |
| US20060234932A1 (en) | 2006-10-19 |
| KR20040064605A (ko) | 2004-07-19 |
| WO2002055152A9 (fr) | 2003-01-23 |
| ES2315350T3 (es) | 2009-04-01 |
| DE60229352D1 (de) | 2008-11-27 |
| JP2004520345A (ja) | 2004-07-08 |
| ZA200305347B (en) | 2004-10-11 |
| EP1351742B1 (fr) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL156828A0 (en) | Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes | |
| EP1511509A4 (fr) | Compositions et procedes de traitement du diabete | |
| PL376473A1 (en) | Treatment of diabetes | |
| MXPA04001525A (es) | Analogos de peptido -1 similar al glucagon. | |
| EP1695983A3 (fr) | Analogues de peptide 1 du type glucagon | |
| WO2000006133A3 (fr) | Procedes et compositions de traitement des interactions moleculaires associees aux glycosaminoglycanes | |
| WO2002018327A3 (fr) | Nouveau guadininobenzamides | |
| EP1285092A4 (fr) | Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique | |
| YU37301A (sh) | Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa | |
| PT1409006E (pt) | Misturas monodispersas e métodos de tratamento de diabetes | |
| NO20003051L (no) | Metode for administrering av AspB28-humant insulin | |
| WO2002053106A3 (fr) | Composition auto-antigene | |
| WO2004043341A3 (fr) | Traitement pour choc hémorragique | |
| MXPA01013384A (es) | Metodos para tratar diabetes. | |
| WO2001026651A3 (fr) | Modulateurs selectifs des recepteurs oestrogeniques pour traiter l'hypertension, des maladies cardio-vasculaires et la resistance a l'insuline ou reduire le risque de contracter ces maladies | |
| MY155219A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide | |
| NO20051390L (no) | Fremgangsmate for behandling av pasienter med massivt blodtap | |
| SI0988302T1 (en) | Benzonaphthyridines | |
| PL348153A1 (en) | Pharmaceutical composition for modified release insulin sensitiser | |
| PT1292315E (pt) | Utilização de sulodexide para o tratamento da neuropatia diabética | |
| WO2003032804A3 (fr) | Methode permettant d'inverser ou d'empecher la senescence vasculaire prematuree | |
| WO2000031530A3 (fr) | Croissance tumorale regulee par p53 et vegf des cellules cancereuses exprimant nos2 | |
| HK1075006A1 (en) | Use of spirolaxine for the preparation of a medicament treating type 2 insulin-resistant diabetes mellitus | |
| HUP0002668A2 (hu) | Diabetes kezelésére dioxo-tiazolidinnel és metforminnal | |
| WO2004037277A3 (fr) | Procede et composition pour la regression du diabete et utilisations correspondantes |